Warning: count(): Parameter must be an array or an object that implements Countable in /home/pulmonx6/public_html/wp-content/themes/specular/includes/view/blog/loop-grid.php on line 53

Pulmonx Names New Chief Executive Officer

Posted by Jenna Widdison
On December 18, 2015

December 18, 2015, Redwood City, California - Pulmonx Corporation, a leader in interventional pulmonology, today announced that Glen French has joined the company as President, Chief Executive Officer and member of the Board of Directors. Mr. French posesses deep experience leading and transforming...

Posted by Jenna Widdison
On December 9, 2015

New England Journal of Medicine Publishes Groundbreaking Study Demonstrating Benefits of Medical Device for Emphysema First Prospective, Randomized Controlled Study Using the Chartis System to Select Patients Confirms Clinical Superiority of Zephyr® EBV Therapy over Medical Management in Treating Emphysema Redwood City, Calif. – December 9, 2015 – Pulmonx Corporation, a leader in interventional pulmonology,...

Posted by Jenna Widdison
On October 18, 2015

London, UK, October 28, 2015 – A clinical trial recently commenced at Royal Brompton Hospital to evaluate a minimally-invasive valve based treatment that may help patients suffering from severe emphysema breathe easier without surgery. Emphysema is a form of chronic obstructive pulmonary disease...

Posted by Jenna Widdison
On September 28, 2015

REDWOOD CITY, Calif. – September 28, 2015 - Pulmonx®, a leader in interventional pulmonology, today announced the launch of a tablet version of its Chartis Pulmonary Assessment System, a diagnostic tool designed to identify optimal patients for Zephyr® Endobronchial Valve (EBV) therapy. The Chartis...

Posted by Jenna Widdison
On July 1, 2015

REDWOOD CITY, Calif. – July 1, 2015 –Pulmonx®, a leader in interventional pulmonology, today announced publication in The Lancet of results from the BeLieVeR-HIFi clinical trial, the first successful sham-controlled trial of any minimally invasive emphysema device. BeLieVeR-HIFi is a prospective,...

Posted by Jenna Widdison
On May 18, 2015

Denver, Colo. – May 18, 2015 –Pulmonx®, a leader in interventional pulmonology, today announced results from a retrospective analysis of the landmark VENT trial that demonstrated a statistically significant benefit in severe emphysema patients with homogeneous disease that received treatment with...

Pulmonx Names New Chief Executive Officer

New England Journal of Medicine Publishes Groundbreaking Study Demonstrating Benefits of Medical Device for Emphysema

Pulmonx Starts UK Clinical Trial at Royal Brompton Hospital with Minimally Invasive Lung Valve Treatment Offering Hope to Emphysema Patients

Pulmonx Launches Chartis Tablet, Simplifying Patient Selection For Zephyr® Endobronchial Valve Therapy

Lancet Publication of Sham-Controlled Clinical Trial Shows Pulmonx’s Zephyr® Endobronchial Valves Deliver Significant Benefit to Emphysema Patients

Zephyr® Endobronchial Valves from Pulmonx® shown to Benefit Severe Emphysema Patients with Homogeneous Disease

Pulmonx Australia Suite 5, Level 6 65 York Street Sydney, NSW 2000 Australia

1300 785 666

info@pulmonx.com.au